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Abstract
Background: Complex interventions are widely used in health systems, public health, education, and communities and are increasingly
the subject of systematic reviews. Oversimplification and inconsistencies in reporting about complex interventions can limit the usability of
review findings.
Rationale: Although guidance exists to ensure that reports of individual studies and systematic reviews adhere to accepted scientific
standards, their design-specific focus leaves important reporting gaps relative to complex interventions in health care. This paper provides
a stand-alone extension to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting tool for complex
interventionsdPRISMA-CIdto help authors, publishers, and readers understand and apply to systematic reviews of complex
interventions.
Discussion: PRISMA-CI development followed the Enhancing the QUAlity and Transparency Of health Research Network guidance
for extensions and focused on adding or modifying only essential items that are truly unique to complex interventions and are not covered
by broader interpretation of current PRISMA guidance. PRISMA-CI provides an important structure and guidance for systematic reviews
and meta-analyses for the highly prevalent and dynamic field of complex interventions. Ó 2017 The Authors. Published by Elsevier Inc.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: Complex interventions; Publishing standards; Research report standards; Health care interventions; Evidence-based medicine; Systematic review;
Research design; Review literature as topic; Guidance as topic

1. Introduction
Funding: This work was funded by the Agency for Healthcare Research &
Quality following contracts HHSA290201200004C, HHSA290201200016I,
and HHSA290201500011I.
Conflicts of interest: The authors have no conflicts of interest to report.
The authors of this report are responsible for its content. Statements in
the report should not be construed as endorsement by the Agency for
Healthcare Research and Quality or the U.S. Department of Health and
Human Services.
* Corresponding author. Tel.: þ1-503-494-2101; fax: þ1-503-2735374.
E-mail address: guisej@ohsu.edu (J.-M. Guise).

This is the sixth in a seven-part series of papers presenting
tools and approaches for Systematic Reviews for Complex
Interventions. This paper represents the collective work in
this special series and introduces a checklist for Preferred
Reporting Items for Systematic Reviews and Meta-analyses
of Complex Interventions (PRISMA-CI).
Systematic reviews have become essential to clinical
guideline development, and an important mechanism to help
clinicians, educators, community practitioners, and public
health workers stay current with practices and advances in

http://dx.doi.org/10.1016/j.jclinepi.2017.06.016
0895-4356/Ó 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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a field. According to recent analyses, the production of systematic reviews has become big business with almost
29,000 systematic reviews published each year resulting in
a ‘‘massive production of unnecessary, misleading, and
conflicted systematic reviews and meta-analyses’’ [1]. As
with any research, the value of a systematic review depends
on the quality and clarity of the product. Reporting
guidelines such as Consolidated Standards Of Reporting
Trials (CONSORT) [2,3], Strengthening The Reporting of
Observational Studies in Epidemiology (STROBE) [4],
Meta-analysis Of Observational Studies in Epidemiology
(MOOSE) [5], and Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) [6] have become
key tools for authors, journals, policy makers, clinicians,
and the public to ensure consistency with accepted standards
and transparency among published reports of research and
systematic reviews. This guidance has been critical to
ensuring scientific rigor and moving the field forward, yet
the design-specific focus leaves important gaps relative to
complex interventions [6,7]. The purpose of this paper
was to increase the quality and usefulness of systematic
reviews and meta-analyses of complex interventions by
providing minimum required reporting guidelines.
Complex interventions are ubiquitous in health care,
education, social services, and community activities. The
Agency for Healthcare Research and Quality (AHRQ), a
US funder of both health services research and evidence
reviews, has seen a rapidly increasing demand for systematic reviews to inform health care decision making about
complex interventions. Although guidance exists for
primary research on complex interventions, guidance for
systematic reviews is missing [8]. A recent AHRQ report
on systematic reviews of complex interventions described
the challenges of conducting such reviews. The report
emphasized a core underlying constraint, that of ‘‘inconsistent reporting of informational details among individual
studies.’’ The absence of these informational details may
pose problems for primary research and synthesis and
potentially limits their usefulness for stakeholders interested in implementing interventions or using information
in systematic reviews [8]. For example, a meta-review of
heart failure programs found that programs generally
worked but flagged concerns about inconsistent and poor
descriptions, which could affect the uptake and implementation of programs [9].
Given the rapidly increasing prominence of complex
interventions in health care, education, and other fields,
authors of systematic reviews increasingly face challenges
in reporting complex interventions. Early concerns about
reporting requirements for meta-analyses of randomized
controlled trials were voiced in the Quality of Reporting
of Meta-analyses guidelines in 1999 [10]. The Preferred
Reporting Items for Systematic Reviews and MetaAnalysis statement [6], published in 2009, extends and
expands these concerns to all systematic reviews, regardless
of design or analysis. The wide use and adoption of these

reporting standards has resulted in improved quality and
consistency of reporting of systematic reviews. Extensions
of PRISMA relate to analysis methods (e.g., network metaanalysis [11], individual patient data [12]); and topical
focus (e.g., equity [13]). PRISMA statements have also
been developed for systematic review abstracts [14] and
protocols [15]. Systematic review of complex interventions
is an important area for which specific guidance is needed
[16e19]. Issues specific to systematic reviews of complex
interventions include the following:
 Scope formulation may need to be more iterative and
involve various inputs to fully explore complexity and
determine a review’s focus [16];
 Key questions may be more complex and explanatory
in naturedin addition to effectiveness, focusing on
how and why an intervention works, for whom an
intervention works or does not work, and under what
circumstances [16];
 More diverse evidence may be required to inform
complex key questions and to explore complexity
[16,17];
 Analysis methods may be more diverse [18,19];
 Explicit inclusion of various sources of complexity,
including greater detail about the intervention, is
needed to understand the review’s conclusions and
improve usefulness of the results for people interested
in implementing findings of systematic reviews [16,17].
In response, we propose the PRISMA-CI checklist to
provide guidance specific to issues for complex interventions
and their methods. A companion document, the PRISMA-CI
Elaboration and Explanation [20], provides guidance on
applying new items in the checklist. These documents
together are intended to improve the transparency and consistency of reporting of systematic reviews and meta-analyses in
any field that encounters complex interventions.
1.1. Terminologyddefinition of complex interventions
PRISMA-CI uses the consolidated definition for
complex interventions, which was put forward by the
Complex Interventions Working Group in the first paper
of this series by Guise et al. [21].

Definition of complex interventions [21]
All complex interventions have two common characteristics: they have
multiple components (intervention complexity) and complicated/
multiple causal pathways, feedback loops, synergies, and/or
mediators and moderators of effect (pathway complexity). In
addition, they may also have one or more of the following three
additional characteristics: target multiple participants, groups, or
organizational levels (population complexity); require multifaceted
adoption, uptake, or integration strategies (implementation
complexity); or work in a dynamic multidimensional environment
(contextual complexity).
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1.2. How do I know if an intervention is complex?

2. Methods

As previously stated in the introductory paper to this
series [21], it is not always readily apparent if an intervention is simple or complex. The primary piece of
advice we offer in this regard is to ask ‘‘What is the
‘it’ that the review focuses on?’’ If the focus of the
review is the effectiveness of taking aspirin after a
myocardial infarction or the effectiveness of one type
of eye protection vs. another to prevent blood splashes
to the eye in surgery, these would not be complex. Biologic or physiologic complexity alone is not sufficient
to be categorized as complex. However, if the review
question is rather how to get patients to increase compliance in taking aspirin after a myocardial infarction, or
which personal protective equipment is best for a system,
these questions are most likely complex. Behavioral
interventions such as medication compliance and system
change often use multiple approaches, target multiple
levels (individual, system, family, provider, etc.), require
multifaceted training and/or adoption, and/or require
special consideration about the environment/context and
available resources. Each of these considerations is a
component of the intervention. As a general rule, public
and population health, community and system-level
interventions, and behavior change are more likely to
be complex than simple.

The protocol for this PRISMA-CI extension was registered on the Enhancing the QUAlity and Transparency Of
health Research (EQUATOR) Network page for reporting
guidelines under development [22]. We followed principles
for the development of research reporting guidelines and
the EQUATOR Network to develop a PRISMA extension
for complex interventions: identifying need, obtaining
funding, reviewing the relevant literature, conducting a
broad survey, and exploring consensus (Fig. 1) [21,23].
Specifically, international multidisciplinary panels of experts in research, reviews, and implementation of complex
interventions participated in a multiphased process over a
3-year period to develop guidance and tools for systematic
reviewers to use when conducting reviews of complex
interventions.
2.1. Literature scan and interviews with national
leaders
We began with a literature scan and interviews with
international leaders in implementation research, systematic reviews, funders, health system leaders, and stakeholders. This work has been published, and it identified
the need for specific guidance for systematic reviews of
complex interventions [24,25]. In the interviews, experts

Fig. 1. Development process for PRISMA-CI checklist. PRISMA-CI, Preferred Reporting Items for Systematic Reviews and Meta-analyses of Complex Interventions.
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raised concerns about inconsistencies in reporting of
publications relating to complex interventions. During the
interviews, experts were asked to identify important
elements or features to report in primary studies or reviews
of complex interventions. These items then informed the
first round of the Delphi process.

2.2. Delphi process
A Delphi process was conducted among an international group of experts in the field of complex intervention research, reviews, and/or implementation to achieve
consensus (Appendix A at www.jclinepi.com). Participants were asked to categorize each item as ‘‘Required,’’
‘‘Suggested,’’ ‘‘Optional,’’ or ‘‘Forget About It.’’ In
addition, participants were asked to provide other items
or revisions in unstructured textboxes. Responses were
analyzed and summary feedback provided in the
following Delphi round. Based on the pattern of responses
from round 1, round 2 participants were asked to categorize each item as either ‘‘Required’’ or ‘‘Optional’’ and
were asked to assign priority by moving that item up or
down on the list. Both Delphi rounds were conducted
electronically (e-Delphi), the first round using SurveyMonkey and subsequently by a custom-made electronic
program that allowed for easy simultaneous allocation
(optional vs. required) and prioritization. All rounds were
completed between April 3, 2015 and June 15, 2015. The
Delphi process was conducted by a research team at
Oregon Health & Science University (OHSU) and
approved by the OHSU institutional review board
(IRB00011642).

2.4. Consensus of expert workgroups
After the in-person meeting, the steering committee and
workgroups (collectively the Complex Intervention Workgroup, Appendix C at www.jclinepi.com) dedicated to the
five content areas participated in twice-monthly workgroup
teleconference calls over 5 months to discuss scope, assign
and coordinate tasks, collect and analyze data, and discuss
and edit draft documents. Each group was asked to provide
text for PRISMA items that needed to be modified or
tailored specifically to reviews of complex interventions.
A supporting explanation and elaboration document was
developed to assist with the application of the PRISMA-CI
extension items [20]. This document was developed collaboratively by the Complex Interventions Steering Committee, through biweekly calls.
2.5. Broad input on the PRISMA-CI extension
After completion, the final PRISMA extension checklist
and accompanying explanation and elaboration papers were
sent to a broad community of international reviewers
(Appendix A at www.jclinepi.com) for input.
2.6. Final consensus
Suggestions and feedback were assembled and reviewed
by the steering committee. The PRISMA-CI Checklist and
Explanation and Elaboration documents were revised in
response and finalized by the committee.

3. Results
3.1. Delphi results

2.3. In-person meeting of experts
A six-person steering committee (Appendix B at www.
jclinepi.com) comprising representatives from international
evidence review groups, methodologists, and funders or
publishers of systematic reviews planned an in-person
conference to develop guidance and tools for complex
intervention systematic review [21]. The group identified
five topic areas in need of specific guidance: (1) framing
the questions of systematic reviews of complex interventions; (2) frameworks and PICOTS; (3) selecting analytic
approaches to systematic reviews of complex interventions;
(4) analytic approaches for complex interventions: best
practices; and (5) reporting elements for systematic reviews
of complex interventions.
Fifty-seven experts in quantitative and qualitative
approaches to systematic reviews and complex interventions met in June, 2015, at AHRQ in Rockville, Maryland.
The elements prioritized in the Delphi were presented at the
meeting for discussion and further refinement. The refined
elements were then matched to relevant items of the
PRISMA.

Delphi participants represented organizations involved in
systematic reviews (Cochrane, US Evidence-based Practice
Centers, US Centers for Disease Control and Prevention
Community Guide, Campbell Collaboration, etc.), policy
and guideline development groups (National Institute for
Health and Care Excellence, World Health Organization),
health care delivery organizations (US Veterans Health
Affairs, Intermountain Healthcare), funders (AHRQ, US
Veterans Health Affairs, US Centers for Disease Control
and Prevention), and individual researchers and research
organizations. Twenty-two of 29 invited participants participated in at least one round of the Delphi (22/29 76% round
1, 23/29 79% round 2). They arrived at consensus on 28
required and 10 optional reporting elements (Appendix D
at www.jclinepi.com).
3.2. Meeting and workgroup input
Meeting participants and workgroups further discussed
and refined the 38 Delphi elements, related to PRISMA
and grouped similar concepts and consolidated them into
only the essential items that are unique to complex
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interventions that could not be covered by broader interpretation of current guidance. Our primary focus for PRISMA-CI
related to characterizing what was unique about the topic of
complex interventions rather than the dimension of analytic
approaches and their associated limitations. We refer readers
interested in unique quantitative and qualitative approaches
to three papers in this series [18,19,26] dedicated to analytic
considerations and to Cochrane qualitative and implementation methods guidance [27].
3.3. Broad input and consensus on PRISMA-CI
extension
The items in the Table 1 are extensions of PRISMA
specific to addressing or analyzing the complexity of interventions included in the review. Of the eight extended items,
one (item 2) concerns clearly identifying the review as
covering complex interventions, and one (item 4) pertains
to providing justification for the specific elements of
complexity under consideration in the review. The remaining six items pertain to aspects of the complexity of the
intervention or its context (11aef).

4. Final PRISMA-CI extension
The Table 1 presents the final set of proposed items for
the PRISMA-CI extension side-by-side with the standard
PRISMA items.
4.1. Applying PRISMA to systematic reviews of complex
interventions
Many PRISMA items (e.g., searches, types of data, and
analytic approaches) did not require revision because, if
interpreted broadly, they would apply to reviews of complex
interventions. For example, although papers in this series
discuss the broad range of information that might be useful
to reviews of complex interventions [16,17] and analytic
approaches that can be used [18,19], we did not believe that
PRISMA items required revision because the existing
elements as written do not prescribe particular approaches.

47

implementation efforts [29]. Consistent reporting about
complexity can further assist people interested in implementing systematic review findings and interventions in
understanding whether, how, and where to apply findings
given their circumstances. Clinical and public health practitioners, professional societies, and policy makers are
increasingly interested in customized or individualized
guidelines. Customized and individualized guidelines
require systematic reviews that explicitly explore sources
of complexity to support applicability to different local
populations, resources, and settings. The PRISMA-CI can
also increase the utility of registries of complex interventions by specifying details related to sources of complexity
to point to important factors to consider when implementing, evaluating, or synthesizing complex interventions.
Input from primary researchers and implementers in the
early stages of development of the PRISMA-CI checklist
anticipated these downstream effects and strengthened it.
Key to the success of this extension is its adoption and use
by authors of systematic reviews. Widespread adoption
requires a balance between the number of reporting elements
and the practicality of reporting. In maintaining this balance,
we focus on the main intent of these reporting guidelinesdto
improve consistency, promote transparency, and improve
usefulness to people who will use, be affected by, or have
an interest in the topic of the evidence review. Achieving this
intent requires including sufficient breadth and depth of
reporting in the most critical implementation areas. We
acknowledge that every source of complexity may not be
relevant for a topic area, nor is it feasible to explore all
sources within a single product. For this reason, we ask
authors to explicitly note the areas of complexity explored
within the review and provide a rationale for this focus.
We anticipate numerous methodological developments
and a vast expansion of primary research and systematic
reviews on complex interventions. As the needs of implementers, researchers, and society change, so will reporting
requirements. We foresee major advances in methodology
and look forward to future efforts in updating and further
specifying this guidance document.
Acknowledgments

5. Discussion
We developed PRISMA-CI Extension to provide guidance to promote consistency and improve the reporting
and usability of systematic reviews on complex interventions. Although the primary focus is on systematic reviews,
we believe this effort nicely complements Template for
intervention Description and replication (TiDier) [28] guidance in the design and reporting of primary research. The
clear and transparent nature of PRISMA-CI may also be
helpful to developers of translational documents such as
clinical practice guidelines and registries. Detailed descriptions of the intervention alone have the potential to improve
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series. The authors would especially like to thank Miguel
Hernan for writing the timing section of the paper. The
authors appreciate Caitlin Dickinson and Nathan Bahr for
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Motu’apuaka for her tireless work coordinating all steering
committee meetings, in-person conferences, and all workgroup activities, and both Makalapua Motu’apuaka and
Lyndzie Sardenga for their assistance on all documents
and coordinating external reviews and comments.
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Table 1. PRISMA-CI extension
Section
Title
Abstract
Structured summary

Introduction
Rationale
Objectives

Methods
Protocol and
registration

Eligibility criteria

Information sources

Search

Study selection

Data collection
process

Data items

Item

Standard PRISMA item

1 Identify the report as a systematic review,
meta-analysis, or both.

Extension for complex interventions
Specifically indicate that the focus of the systematic
review includes a ‘‘complex intervention’’

2 Provide a structured summary including, as applicable:
background; objectives; data sources; study eligibility
criteria, participants, and interventions; study
appraisal and synthesis methods; results; limitations;
conclusions and implications of key findings;
systematic review registration number.
3 Describe the rationale for the review in the context of
what is already known.
4 Provide an explicit statement of questions being
addressed with reference to PICOS

Include in this statement the sources of complexity of
primary interest (see definition of complex
intervention)

5 Indicate if a review protocol exists, if and where it can
be accessed (e.g., Web address), and, if available,
provide registration information including registration
number.
6 Specify study characteristics (e.g., PICOS, length of
follow-up) and report characteristics (e.g., years
considered, language, publication status) used as
criteria for eligibility, giving rationale.
7 Describe all information sources (e.g., databases with
dates of coverage, contact with study authors to
identify additional studies) in the search and date last
searched
8 Present full electronic search strategy for at least one
database, including any limits, used, such that it
could be repeated.
9 State the process for selecting studies (i.e., screening,
eligibility, included in systematic review, and, if
applicable, included in the meta-analysis).
10 Describe method of data extraction from reports (e.g.,
piloted forms, independently, in duplicate and any
processes for obtaining and conforming data from
investigators).
11 List and define all variables for which data were sought
(e.g., PICOTS funding sources) and any assumptions
and simplifications made.
11a
Pathway complexity: include an analytic framework,
causal pathway, or other graphical representation of
the chain of evidence to illustrate the complexity of
the causal pathway
11b
Intervention complexity: include sufficient detail for the
interventions’ components (including number,
sequence, active vs. discretionary, a priori vs. final),
frequency, duration, intensity, theoretical foundation,
incentives, replicability, and people delivering the
intervention.
11c
Population complexity: include sufficient detail to
describe who (or what system level) the intervention
targeted and the characteristics of the participants
(e.g., age, gender, ethnicity, language, educational or
skill level, medical and social risk status, etc.).
11d
Implementation complexity: clearly define the adoption,
uptake, or integration strategies. Strategies can
include facilitators (distinct from intervention
elements) such as including attestations, financial
incentives, periodic reports of findings, reminders,
supplemental trainings, or physical environmental
changes.
(Continued )
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Table 1. Continued
Section

Item

Standard PRISMA item

11e

11f

Risk of bias in
individual studies

Summary measures
Synthesis of results

Risk of bias
across studies
Additional analyses

Results
Study selection

Study characteristics

Risk of bias within
studies
Results of individual
studies

Synthesis of results
Risk of bias across
studies
Additional analysis
Discussion
Summary of evidence

Limitations

Conclusions
Funding
Funding

Extension for complex interventions
Settingdcontextual complexity: include detail about
the settings, locations where the data were collected,
or other contextual factors (including financial,
organizational, and clinical setting). Provide rationale
if not relevant.
Timing: describe the absolute and relative timing of
each of the components of PICO. Specifically,
describe the time at which eligibility criteria (P) were
set, the time at which the interventions or treatment
strategies (I, C) were assigned, and the time zero of
follow-up when outcome events started to be
counted. In addition, describe the timing of the
components of interventions I and C during the
follow-up. Provide rationale if not relevant.

12 Describe methods used for assessing risk of bias of
individual studies (including specification of whether
this was done at the study or outcome level), and how
this information is to be used in any data synthesis
13 State the principal summary measures (e.g., risk ratio,
difference in means).
14 Describe the methods of handling data and combining
results of studies, if done, including measures of
consistency (e.g., I2) for each meta-analysis
15 Specify any assessment of risk of bias that may affect
the cumulative evidence (e.g., publication bias,
selective reporting within studies)
16 Describe methods of additional analyses (e.g.,
sensitivity or subgroup analyses, meta-regression), if
done, indicating which were prespecified.
17 Give numbers of studies screened, assessed for
eligibility, and included in the review, with reasons for
exclusions at each stage, ideally with a flow diagram.
18 For each study, present characteristics for which data
were extracted (e.g., study size, PICOS, follow-up
period) and provide the citations.
19 Present data on risk of bias of each study and, if
available, any outcome level assessment (see item 12).
20 For all outcomes considered (benefits or harms),
present, for each study: (1) simple summary data for
each intervention group; (2) effect estimates and
confidence intervals, ideally with a forest plot.
21 Present results of each meta-analysis done, including
confidence intervals and measures of consistency.
22 Present results of any assessment of risk of bias across
studies (see item 15).
23 Give results of additional analyses, if done (e.g., sensitivity
or subgroup analyses, meta-regression [see item 16]).
24 Summarize the main findings including the strength of
evidence for each main outcome; consider their
relevance to key groups (e.g., health care providers,
users, and policy makers)
25 Discuss limitations at study and * outcome level (e.g.,
risk of bias), and at review-level (e.g., incomplete
retrieval of identified research, reporting bias).
26 Provide a general interpretation of the results in the context
of other evidence and implications for future research.
27 Describe sources of funding for the systematic review
and other support (e.g., supply of data); role of
funders for the systematic review.

Abbreviation: PRISMA-CI, Preferred Reporting Items for Systematic Reviews and Meta-analyses of Complex Interventions.
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Supplementary Data
Supplementary data related to this article can be found at
http://dx.doi.org/10.1016/j.jclinepi.2017.06.016.
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